In vitro studies on the mechanisms of oxaliplatin resistance

Cancer Chemotherapy and Pharmacology

Volumn 48, Issue 5, 2001, Pages 398-406

  Hector, S ^a   Bolanowska Higdon, W ^a   Zdanowicz, J ^a   Hitt, S ^a   Pendyala, L ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

Accumulation; Adducts; Cisplatin; Oxaliplatin; Resistance

Indexed keywords

CISPLATIN; MESSENGER RNA; NOLATREXED; OXALIPLATIN; PLATINUM; SULFORHODAMINE B;

ARTICLE; ASSAY; ATOMIC ABSORPTION SPECTROMETRY; CARCINOMA CELL; COLON CARCINOMA; CONTROLLED STUDY; CROSS RESISTANCE; CYTOTOXICITY; DNA ADDUCT; DNA BINDING; DNA REPAIR; DRUG ACCUMULATION; DRUG MECHANISM; HUMAN; HUMAN CELL; IN VITRO STUDY; OVARY CARCINOMA; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ANTINEOPLASTIC AGENTS; DNA ADDUCTS; DNA REPAIR; DNA-BINDING PROTEINS; DRUG RESISTANCE, NEOPLASM; ENDONUCLEASES; HT29 CELLS; HUMANS; ORGANOPLATINUM COMPOUNDS; PLATINUM; PROTEINS; RNA, MESSENGER;

EID: 0034761598     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002800100363     Document Type: Article

References (40)

1. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding
2. Specificity of platinum-DNA adduct repair
3. Single agent activity of oxaliplatin in heavily pretreated advanced epithelial ovarian cancer
4. Cellular responses to cisplatin. The roles of DNA-binding proteins and DNA repair
5. Oxaliplatin with high dose leucovorin and 5-fluorouracil 48-hour continuous infusion in pretreated metastatic colorectal cancer
6. Altered glutathione metabolism in oxaliplatin resistant A2780 ovarian carcinoma cells
7. Phase I study of oxaliplatin in patients with advanced cancer
8. Pharmacokinetics and safety profile of oxaliplatin
9. The role of DNA mismatch repair in platinum drug resistance
10. In vitro and in vivo resistance to cisplatin in cells that have lost DNA mismatch repair
11. The role of DNA mismatch repair in drug resistance
12. Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer
13. Insights into mechanisms of cisplatin resistance and potential for its clinical reversal
14. Platinum antitumor agents: A review of (bio) analysis
15. Quantitation of dihydropyrimidine dehydrogenase expression by real-time reverse transcription polymerase chain reaction
16. Role of platinum-DNA adduct formation and removal in cisplatin resistance in human ovarian cancer cell lines
17. DNA repair capacity and cisplatin sensitivity of human testis tumour cells
18. Oxaliplatin: Pharmacokinetics and chronopharmacological aspects
19. Enhanced replicative bypass of platinum-DNA adducts in cisplatin-resistant human ovarian carcinoma cell lines
20. Oxalatoplatinum (1-OHP): Experimental and clinical studies
21. Induction of JNK and cAbl signaling by cisplatin and oxaliplatin in mismatch repair-proficient and deficient cells
22. In vitro cytotoxicity, protein binding, red blood cell partitioning and biotransformation of oxaliplatin
23. Cytotoxicity, cellular accumulation and DNA binding of oxaliplatin isomers
24. Analysis of total platinum in tissue samples by flameless atomic absorption spectrophotometry. Elimination of the need for sample digestion
25. Antitumor activity of oxaliplatin in combination with 5-fluorouracil and the thymidylate synthase inhibitor AG337 in human colon, breast and ovarian cancers
26. Oxaliplatin: Mechanism of action and antineoplastic activity
27. Efficient nucleotide excision repair of cisplatin, oxaliplatin and bis-acetato-ammine-dichloro-cyclohexylamine-platinum (IV) (JM216) platinum intrastrand DNA diadducts
28. Nucleotide excision repair and anti-cancer chemotherapy
29. Oxaliplatin, tetraplatin, cisplatin and carboplatin: Spectrum of activity in drug-resistant cell lines and in the cell lines of the National Cancer Institute's anticancer drug screen panel
30. Comparison of in vitro anticancer drug screening data generated with a tetrazolium assay versus a protein assay against a diverse panel of human tumor cell lines
31. DNA excision repair
32. In vitro formation of DNA adducts by cisplatin, lobaplatin and oxaliplatin in calf thymus DNA in solution and in cultured human cells
33. Molecular modelling of the intrastrand guanine-guanine DNA adducts produced by cisplatin and oxaliplatin
34. Pharmacokinetic modeling of oxaliplatin with and without 5-FU and radiation
35. Molecular cloning of the human nucleotide-excision-repair gene ERCC4
36. The role of hMLH1, hMSH3 and hMSH6 defects in cisplatin and oxaliplatin resistance: Correlations with replicative bypass of platinum-DNA adducts
37. Oxaliplatin. A review of its use in the management of metastatic colorectal cancer
38. Sequence- and region-specificity of oxaliplatin adducts in naked and cellular DNA
39. Oxaliplatin-induced damage of cellular DNA
40. Alternative splicing of ERCC1 and cisplatin-DNA adduct repair in human tumor cell lines